BidaskClub cut shares of Acadia Healthcare (NASDAQ:ACHC) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday.
Several other research firms also recently weighed in on ACHC. ValuEngine downgraded Acadia Healthcare from a hold rating to a sell rating in a research note on Saturday, April 7th. BMO Capital Markets restated an outperform rating and issued a $45.00 price target (up from $40.00) on shares of Acadia Healthcare in a research note on Friday, February 23rd. Royal Bank of Canada restated a buy rating and issued a $45.00 price target on shares of Acadia Healthcare in a research note on Tuesday, February 27th. Cantor Fitzgerald upgraded Acadia Healthcare from a neutral rating to an overweight rating in a research note on Sunday, February 25th. Finally, Credit Suisse Group restated a neutral rating and issued a $40.00 price target (up from $35.00) on shares of Acadia Healthcare in a research note on Thursday, February 22nd. One analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $44.50.
Acadia Healthcare stock opened at $38.90 on Tuesday. The company has a market capitalization of $3,425.00, a P/E ratio of 16.91, a PEG ratio of 1.27 and a beta of 0.63. Acadia Healthcare has a 12-month low of $26.92 and a 12-month high of $54.34. The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 1.25.
Acadia Healthcare (NASDAQ:ACHC) last released its earnings results on Wednesday, February 21st. The company reported $0.61 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.07. Acadia Healthcare had a net margin of 6.92% and a return on equity of 8.16%. The company had revenue of $724.50 million during the quarter, compared to analyst estimates of $713.20 million. During the same period in the prior year, the firm posted $0.59 EPS. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. analysts forecast that Acadia Healthcare will post 2.45 EPS for the current year.
In other news, Director Reeve B. Waud sold 42,302 shares of the stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $42.02, for a total transaction of $1,777,530.04. Following the completion of the transaction, the director now directly owns 10,088 shares in the company, valued at approximately $423,897.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Reeve B. Waud sold 7,698 shares of the stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $42.03, for a total value of $323,546.94. Following the transaction, the director now owns 10,088 shares of the company’s stock, valued at $423,998.64. The disclosure for this sale can be found here. Insiders have sold a total of 401,360 shares of company stock valued at $15,759,096 over the last quarter. Corporate insiders own 2.50% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of ACHC. Freshford Capital Management LLC bought a new position in shares of Acadia Healthcare during the 4th quarter valued at approximately $31,835,000. Frontier Capital Management Co. LLC boosted its position in shares of Acadia Healthcare by 13.2% during the 4th quarter. Frontier Capital Management Co. LLC now owns 2,903,403 shares of the company’s stock valued at $94,738,000 after acquiring an additional 337,961 shares during the last quarter. Sapience Investments LLC bought a new position in shares of Acadia Healthcare during the 4th quarter valued at approximately $10,279,000. Aristotle Capital Management LLC boosted its position in shares of Acadia Healthcare by 5.0% during the 4th quarter. Aristotle Capital Management LLC now owns 6,183,866 shares of the company’s stock valued at $201,780,000 after acquiring an additional 297,069 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Acadia Healthcare by 11.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,662,663 shares of the company’s stock valued at $79,408,000 after acquiring an additional 176,020 shares during the last quarter.
WARNING: “Acadia Healthcare (ACHC) Downgraded by BidaskClub to “Buy”” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/18/acadia-healthcare-achc-downgraded-by-bidaskclub-to-buy.html.
Acadia Healthcare Company Profile
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.